Meribank Biotech Co Ltd Statistics
Meribank Biotech Co Ltd (4724) Stock Statistics & Valuation Metrics
Total Valuation
Meribank Biotech Co Ltd has a market cap or net worth of TWD 852.27M. The enterprise value is ―.
- Market Cap
- TWD 852.27M
- Enterprise Value
- ―
Share Statistics
Meribank Biotech Co Ltd has 95,976,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 95,976,400
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Meribank Biotech Co Ltd’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -1.76%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.03
- Return on Invested Capital (ROIC)
- -1.76%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 3.32M
- Profits Per Employee
- -573.70K
- Employee Count
- 142
- Asset Turnover
- 0.16
- Inventory Turnover
- 41.97
Valuation Ratios
The current PE Ratio of Meribank Biotech Co Ltd is -6.40. Meribank Biotech Co Ltd’s PEG ratio is 0.09.
- PE Ratio
- -6.40
- PS Ratio
- 2.16
- PB Ratio
- 0.75
- Price to FCF
- 14.66
- Price to Operating Cash Flow
- 12.62
- PEG Ratio
- 0.09
Income Statement
In the last 12 months, Meribank Biotech Co Ltd had revenue of 471.76M and earned -81.47M in profits. Earnings per share was -0.89.
- Revenue
- 471.76M
- Gross Profit
- 202.18M
- Operating Income
- -52.78M
- Pretax Income
- -88.94M
- Net Income
- -81.47M
- EBITDA
- 102.63M
- Earnings Per Share (EPS)
- -0.89
Cash Flow
In the last 12 months, operating cash flow was 70.03M and capital expenditures -9.72M, giving a free cash flow of 60.31M billion.
- Operating Cash Flow
- 70.03M
- Free Cash Flow
- 60.31M
- Free Cash Flow per Share
- 0.63
Dividends & Yields
Meribank Biotech Co Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 7.17%
- Earnings Yield
- -16.05%
Stock Price Statistics
- Beta
- 0.33
- 52-Week Price Change
- -48.97%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 42.72
- Average Volume (3m)
- 93.70K
Financial Position
Meribank Biotech Co Ltd as a current ratio of 1.90, with Debt / Equity ratio of 90.27%
- Current Ratio
- 1.90
- Quick Ratio
- 1.88
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 10.04
- Interest Coverage Ratio
- -2.28
Taxes
In the past 12 months, Meribank Biotech Co Ltd has paid -6.78M in taxes.
- Income Tax
- -6.78M
- Effective Tax Rate
- 0.08
Enterprise Valuation
Meribank Biotech Co Ltd EV to EBITDA ratio is 32.38, with an EV/FCF ratio of 30.80.
- EV to Sales
- 4.55
- EV to EBITDA
- 32.38
- EV to Free Cash Flow
- 30.80
- EV to Operating Cash Flow
- 26.52
Balance Sheet
Meribank Biotech Co Ltd has TWD 191.32M in cash and marketable securities with TWD 1.09B in debt, giving a net cash position of -TWD 893.80M billion.
- Cash & Marketable Securities
- TWD 191.32M
- Total Debt
- TWD 1.09B
- Net Cash
- -TWD 893.80M
- Net Cash Per Share
- -TWD 9.31
- Tangible Book Value Per Share
- TWD 3.95
Margins
Gross margin is 34.99%, with operating margin of -25.87%, and net profit margin of -33.07%.
- Gross Margin
- 34.99%
- Operating Margin
- -25.87%
- Pretax Margin
- -34.94%
- Net Profit Margin
- -33.07%
- EBITDA Margin
- 14.05%
- EBIT Margin
- -25.87%
Analyst Forecast
The average price target for Meribank Biotech Co Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -16.04%
- EPS Growth Forecast
- -88.60%
